
    
      Patients who qualify for the study will receive 7 bi-weekly LDL-Apheresis treatments with the
      Kaneka Liposorber device. Patients will assess their CHF symptoms using the KC Cardiomyopathy
      questionnaire prior to each treatment. Blood levels of certain indices related to CHF and
      safety profile labs will be drawn before and after the first and last treatment.
    
  